ArticleActa biomaterialia2020
Nanoparticles for multimodal antivascular therapeutics: Dual drug release, photothermal and photodynamic therapy.
Article in Acta biomaterialia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 75 citations in OpenAlex.
- Mesoporous Silica Nanoparticles in Biomedicine: Advances and Prospects.Advanced materials (Deerfield Beach, Fla.) · 2026Review
- Intranasally delivered fucoidan nanozyme-decorated photosyntheticMaterials today. Bio · 2026Article
- Evaluation of the Dual Impact of Nanotechnologies on Health and Environment Through Alternative Bridging Models.Advanced healthcare materials · 2026Review
- Advances in nanocarrier-mediated cancer therapy: Progress in immunotherapy, chemotherapy, and radiotherapy.Chinese medical journal · 2025Review
- Doxycycline-Induced Apoptosis inInfection and drug resistance · 2025Article
- Nano-based Theranostics Approach in the Management of Cancer: Review.Pharmaceutical nanotechnology · 2025Review
- Nanocarriers for targeted drug delivery in the vascular system: focus on endothelium.Journal of nanobiotechnology · 2024Review
- Bioproduced Nanoparticles Deliver Multiple Cargoes via Targeted Tumor Therapy In Vivo.ACS omega · 2024Article
- Unraveling Endothelial Cell Migration: Insights into Fundamental Forces, Inflammation, Biomaterial Applications, and Tissue Regeneration Strategies.ACS applied bio materials · 2024Review
- Quantum Dot-based Bio-conjugates as an Emerging Bioimaging Tool for Cancer Theranostic- A Review.Current drug targets · 2024Review
- Influence of Pore Size in Protein G'-Grafted Mesoporous Silica Nanoparticles as a Serum Pretreatment System for In Vitro Allergy Diagnosis.Advanced healthcare materials · 2023Article
- Review
- Nanomaterial-Based Antivascular Therapy in the Multimodal Treatment of Cancer.Pharmaceutics · 2023Review
- Integrated transcriptomics and metabolomics analysis reveals the biomolecular mechanisms associated to the antitumoral potential of a novel silver-based core@shell nanosystem.Mikrochimica acta · 2023Article
- Multimeric RGD-Based Strategies for Selective Drug Delivery to Tumor Tissues.Pharmaceutics · 2023Review
- Natural Biopolymers as Smart Coating Materials of Mesoporous Silica Nanoparticles for Drug Delivery.Pharmaceutics · 2023Review
- Nanomedical research and development in Spain: improving the treatment of diseases from the nanoscale.Frontiers in bioengineering and biotechnology · 2023Review
- Advances in nanomaterial-based targeted drug delivery systems.Frontiers in bioengineering and biotechnology · 2023Review
- Nanomaterials and Nanostructures Hand-In-Hand with Biology.Nanomaterials (Basel, Switzerland) · 2022Article
- Combination of phototherapy with immune checkpoint blockade: Theory and practice in cancer.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
The poor delivery of nanoparticles to target cancer cells hinders their success in the clinical setting. In this work, an alternative target readily available for circulating nanoparticles has been selected to eliminate the need for nanoparticle penetration in the tissue: the tumor blood vessels. A tumor endothelium-targeted nanoparticle (employing an RGD-containing peptide) capable of co-delivering two anti-vascular drugs (one anti-angiogenic drug and one vascular disruption agent) is here presented. Furthermore, the nanodevice presents two additional anti-vascular capabilities upon activation by Near-Infrared light: provoking local hyperthermia (by gold nanorods in the system) and generating toxic reactive oxygen species (by the presence of a photosensitizer). RGD-targeting is shown to increase uptake by HUVEC cells, and while the nanoparticles are shown not to be toxic for these cells, upon Near-Infrared irradiation their almost complete killing is achieved. The combination of all four therapeutic modalities is then evaluated in an ex ovo fibrosarcoma xenograft model, which shows a significant reduction in the number of blood vessels irrigating the xenografts when the nanoparticles are present, as well as the destruction of the existing blood vessels upon irradiation. These results suggest that the combination of different anti-vascular therapeutic strategies in a single nanocarrier appears promising and should be further explored in the future. STATEMENT OF SIGNIFICANCE MVR2019: The combination of antivascular drugs with different mechanisms of action (such as antiangiogenic drugs and vascular disruption agents) has been recently proposed as a promising approach to maximize the therapeutic potential of anti-vascular therapeutics. Given the capacity of nanoparticles to co-deliver different drugs in optimizable ratios, nanomedicine appears to have a huge potential for the development of this kind of multimodal antivascular. To showcase this, an multimodal anti-vascular nanodevice for cancer therapy is here presented. This tumor endothelium-targeted nanosystem is capable of co-delivering two anti-vascular drugs (anti-angiogenic and vascular disruption agent) while also providing two additional therapeutic modalities that can be activated by Near-Infrared light: provoking local hyperthermia (photothermal therapy) and generating toxic reactive oxygen species (photodynamic therapy).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.